- Home
- ESS vs WAT Comparison
ESS vs WAT Comparison
Compare ESS & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESS
- WAT
- Stock Information
- Founded
- ESS 1971
- WAT 1958
- Country
- ESS United States
- WAT United States
- Employees
- ESS N/A
- WAT N/A
- Industry
- ESS Real Estate Investment Trusts
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- ESS Real Estate
- WAT Industrials
- Exchange
- ESS Nasdaq
- WAT Nasdaq
- Market Cap
- ESS 16.9B
- WAT 17.4B
- IPO Year
- ESS 1994
- WAT 1995
- Fundamental
- Price
- ESS $259.86
- WAT $371.80
- Analyst Decision
- ESS Hold
- WAT Buy
- Analyst Count
- ESS 18
- WAT 13
- Target Price
- ESS $296.26
- WAT $379.00
- AVG Volume (30 Days)
- ESS 579.0K
- WAT 670.2K
- Earning Date
- ESS 10-29-2025
- WAT 11-04-2025
- Dividend Yield
- ESS 3.95%
- WAT N/A
- EPS Growth
- ESS 53.64
- WAT 3.82
- EPS
- ESS 13.15
- WAT 10.88
- Revenue
- ESS $1,916,711,000.00
- WAT $3,105,638,000.00
- Revenue This Year
- ESS $4.02
- WAT $7.12
- Revenue Next Year
- ESS $3.80
- WAT $6.22
- P/E Ratio
- ESS $19.81
- WAT $34.17
- Revenue Growth
- ESS 9.37
- WAT 6.90
- 52 Week Low
- ESS $243.25
- WAT $275.05
- 52 Week High
- ESS $316.29
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- ESS 51.06
- WAT 71.44
- Support Level
- ESS $247.40
- WAT $340.09
- Resistance Level
- ESS $261.51
- WAT $382.02
- Average True Range (ATR)
- ESS 5.74
- WAT 11.25
- MACD
- ESS 0.43
- WAT 1.45
- Stochastic Oscillator
- ESS 71.20
- WAT 75.62
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 258 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.